Pharmaceutical Contract Development & Manufacturing Market Research Report by Service, End User, Country - North America Forecast to 2027 - Cumulative Impact of COVID-19

The North America Pharmaceutical Contract Development & Manufacturing Market size was estimated at USD 24.94 billion in 2021 and expected to reach USD 27.01 billion in 2022, and is projected to grow at a CAGR 8.57% to reach USD 40.87 billion by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Pharmaceutical Contract Development & Manufacturing to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Service, the market was studied across Biologics Manufacturing Services, Drug Development Services, Pharmaceutical Manufacturing Services, and Secondary Packaging Services. The Biologics Manufacturing Services is further studied across Biologics API Manufacturing Services and Biologics FDF Manufacturing Services. The Pharmaceutical Manufacturing Services is further studied across Pharmaceutical API Manufacturing and Pharmaceutical FDF Manufacturing. The Pharmaceutical API Manufacturing is further studied across Capsule Manufacturing Services, Oral Liquid Manufacturing Services, Parenteral/Injectable Manufacturing Services, and Tablet Manufacturing Services.

Based on End User, the market was studied across Big Pharma, Generic Pharmaceutical Companies, and Small & Mid-Size Pharma.

Based on Country, the market was studied across Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Pharmaceutical Contract Development & Manufacturing market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Pharmaceutical Contract Development & Manufacturing Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the North America Pharmaceutical Contract Development & Manufacturing Market, including AbbVie, Inc., Aenova Group GmbH, Almac Group, AMRI Global, C.H. Boehringer Sohn AG & Ko. KG, Cambrex Corporation, Catalent, Inc., Danaher Corporation, Delwis Healthcare Pvt Ltd., Evonik Industries AG, Famar Health Care Services, Fareva, Jubilant Life Sciences Limited, Lonza Group AG, Pfizer Inc., Recipharm AB, Serum Institute of India Ltd., Siegfried Holding AG, Thermo Fisher Scientific Inc., and Vetter Pharma-Fertigung GmbH & Co. KG.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the North America Pharmaceutical Contract Development & Manufacturing Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the North America Pharmaceutical Contract Development & Manufacturing Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the North America Pharmaceutical Contract Development & Manufacturing Market?
4. What is the competitive strategic window for opportunities in the North America Pharmaceutical Contract Development & Manufacturing Market?
5. What are the technology trends and regulatory frameworks in the North America Pharmaceutical Contract Development & Manufacturing Market?
6. What is the market share of the leading vendors in the North America Pharmaceutical Contract Development & Manufacturing Market?
7. What modes and strategic moves are considered suitable for entering the North America Pharmaceutical Contract Development & Manufacturing Market?

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19

6. Pharmaceutical Contract Development & Manufacturing Market, by Service
6.1. Introduction
6.2. Biologics Manufacturing Services
6.3.1. Biologics API Manufacturing Services
6.3.2. Biologics FDF Manufacturing Services
6.3. Drug Development Services
6.4. Pharmaceutical Manufacturing Services
6.5.1. Pharmaceutical API Manufacturing
6.5.2.1. Capsule Manufacturing Services
6.5.2.2. Oral Liquid Manufacturing Services
6.5.2.3. Parenteral/Injectable Manufacturing Services
6.5.2.4. Tablet Manufacturing Services
6.5.2. Pharmaceutical FDF Manufacturing
6.5. Secondary Packaging Services

7. Pharmaceutical Contract Development & Manufacturing Market, by End User
7.1. Introduction
7.2. Big Pharma
7.3. Generic Pharmaceutical Companies
7.4. Small & Mid-Size Pharma

8. Canada Pharmaceutical Contract Development & Manufacturing Market
8.1. Introduction

9. Mexico Pharmaceutical Contract Development & Manufacturing Market
9.1. Introduction

10. United States Pharmaceutical Contract Development & Manufacturing Market
10.1. Introduction

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. AbbVie, Inc.
12.1.1. Business Overview
12.1.2. Key Executives
12.1.3. Product & Services
12.2. Aenova Group GmbH
12.2.1. Business Overview
12.2.2. Key Executives
12.2.3. Product & Services
12.3. Almac Group
12.3.1. Business Overview
12.3.2. Key Executives
12.3.3. Product & Services
12.4. AMRI Global
12.4.1. Business Overview
12.4.2. Key Executives
12.4.3. Product & Services
12.5. C.H. Boehringer Sohn AG & Ko. KG
12.5.1. Business Overview
12.5.2. Key Executives
12.5.3. Product & Services
12.6. Cambrex Corporation
12.6.1. Business Overview
12.6.2. Key Executives
12.6.3. Product & Services
12.7. Catalent, Inc.
12.7.1. Business Overview
12.7.2. Key Executives
12.7.3. Product & Services
12.8. Danaher Corporation
12.8.1. Business Overview
12.8.2. Key Executives
12.8.3. Product & Services
12.9. Delwis Healthcare Pvt Ltd.
12.9.1. Business Overview
12.9.2. Key Executives
12.9.3. Product & Services
12.10. Evonik Industries AG
12.10.1. Business Overview
12.10.2. Key Executives
12.10.3. Product & Services
12.11. Famar Health Care Services
12.11.1. Business Overview
12.11.2. Key Executives
12.11.3. Product & Services
12.12. Fareva
12.12.1. Business Overview
12.12.2. Key Executives
12.12.3. Product & Services
12.13. Jubilant Life Sciences Limited
12.13.1. Business Overview
12.13.2. Key Executives
12.13.3. Product & Services
12.14. Lonza Group AG
12.14.1. Business Overview
12.14.2. Key Executives
12.14.3. Product & Services
12.15. Pfizer Inc.
12.15.1. Business Overview
12.15.2. Key Executives
12.15.3. Product & Services
12.16. Recipharm AB
12.16.1. Business Overview
12.16.2. Key Executives
12.16.3. Product & Services
12.17. Serum Institute of India Ltd.
12.17.1. Business Overview
12.17.2. Key Executives
12.17.3. Product & Services
12.18. Siegfried Holding AG
12.18.1. Business Overview
12.18.2. Key Executives
12.18.3. Product & Services
12.19. Thermo Fisher Scientific Inc.
12.19.1. Business Overview
12.19.2. Key Executives
12.19.3. Product & Services
12.20. Vetter Pharma-Fertigung GmbH & Co. KG
12.20.1. Business Overview
12.20.2. Key Executives
12.20.3. Product & Services

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing